Efficacy of EUS-RFA in pancreatic tumors: Is it ready for prime time? A systematic review and meta-analysis.

Published on Sep 22, 2020in Endoscopy International Open
· DOI :10.1055/A-1221-5012
Amaninder Dhaliwal6
Estimated H-index: 6
(UNMC: University of Nebraska Medical Center),
Sindhura Kolli5
Estimated H-index: 5
(NYU: New York University)
+ 9 AuthorsDouglas G. Adler65
Estimated H-index: 65
(UofU: University of Utah)
Background and study aims Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) can be used in patients with unresectable pancreatic ductal adenocarcinoma (PDAC). We performed a systematic review and meta-analysis to evaluate the efficacy of EUS-RFA in treatment of locally advanced unresectable PDAC and other pancreatic tumors. Patients and methods A comprehensive search was done of multiple electronic databases and conference proceedings including PubMed, EMBASE, Web of Science databases, Google Scholar and manual search of references (from inception through May 2019) to identify the studies reporting use of EUS-RFA for pancreatic lesions. The primary outcome was to evaluate technical and clinical success of the procedure. The secondary outcome was to study overall adverse events (AEs). Results Thirteen studies reporting 165 EUS-RFA procedures on 134 patients were included. Of 134 patients, 27.94 % (38) had unresectable locally advanced PDAC, 40 % (53) had PNETs, 3 % (4) had metastasis to the pancreas and 30 % (41) had other lesions. The pooled technical success rate calculated out of the total number of procedures was 100 % (95 % CI [99.18 – 100], I2 = 0 %). The pooled clinical success rate calculated out of the total number of patients was 91.58 % (95 % CI [82.5 – 98.08], I2 = 21.5 %). The pooled overall AE rates were 14.67 % (95 % CI [4.77 – 27.46], I2 = 56.19 %) out of which abdominal pain was the most common with 9.82 % (95 % CI [3.34 – 18.24], I2 = 23.76 %). Low to moderate heterogeneity was noted. Conclusion EUS-RFA has high technical (100 %) and clinical success (91.5 %) rates. Further multicenter trials are needed to further validate our findings.
#1Kira Oleinikov (HUJI: Hebrew University of Jerusalem)H-Index: 4
#2Alain Dancour (Shaare Zedek Medical Center)H-Index: 6
Last. Simona Grozinsky-Glasberg (HUJI: Hebrew University of Jerusalem)H-Index: 26
view all 13 authors...
CONTEXT: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is rapidly emerging as feasible therapy for patients with pancreatic neuroendocrine tumors (pNETs) in selected cases, as a result of its favorable safety profile. OBJECTIVE: To assess the feasibility, safety, and efficacy of EUS-RFA in a cohort of patients with functional and nonfunctional pNETs (NF-pNETs). DESIGN: Data on pNET patients treated with EUS-RFA between March 2017 and October 2018 at two tertiary centers was retr...
24 CitationsSource
#1Alberto Larghi (FUI: Foundation University, Islamabad)H-Index: 8
#2Gianenrico Rizzatti (FUI: Foundation University, Islamabad)H-Index: 11
Last. Guido Costamagna (UDS: University of Strasbourg)H-Index: 9
view all 6 authors...
Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumors, but their incidental diagnosis has significantly increased due to the widespread use of imaging studies. Therefore, most PanNENs are now diagnosed when completely asymptomatic and in early stages. PanNENs are classified according to their grade (Ki-67 index) and can be functional (F-) or nonfunctional (NF-) depending on the presence or absence of a clinical, hormonal hypersecretion syndrome. The mainstay treatment of PanNENs is a sur...
14 CitationsSource
#1Marc Barthet (AMU: Aix-Marseille University)H-Index: 25
#2Marc GiovanniniH-Index: 60
Last. Jean-Michel Gonzalez (AMU: Aix-Marseille University)H-Index: 15
view all 9 authors...
Background Pancreatic neuroendocrine tumors (NETs) and intraductal pancreatic mucinous neoplasia (IPMN) with worrisome features are surgically managed. Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) has recently been developed. The safety of EUS-RFA was the primary end point of this study, its efficacy the secondary end point. Methods This was a prospective multicenter study that was planned to include 30 patients with a 1-year follow-up with either a NET Results 12 patients ha...
58 CitationsSource
#1Maximilien Barret (Paris V: Paris Descartes University)H-Index: 19
#2Sarah Leblanc (Paris V: Paris Descartes University)H-Index: 14
Last. Frederic Prat (Paris V: Paris Descartes University)H-Index: 33
view all 6 authors...
Introduction Two devices are currently available to perform pancreatic radiofrequency ablation (P-RFA). Potential clinical indications might extend from the treatment of pancreatic cystic lesions to ablation of small pancreatic solid lesions or cytoreduction of advanced pancreatic adenocarcinomas, but more preclinical data from animal models are needed to optimize P-RFA operation. Methods P-RFA was performed under laparotomy and under endoscopic ultrasonographic guidance on the liver and pancrea...
8 CitationsSource
2 CitationsSource
#1Nirav Thosani (University of Texas Health Science Center at Houston)H-Index: 23
#2Neil SharmaH-Index: 6
Last. Sushovan Guha (University of Texas Health Science Center at Houston)H-Index: 51
view all 8 authors...
6 CitationsSource
#1Filippo ScopellitiH-Index: 5
#2Antonio Pea (University of Verona)H-Index: 19
Last. Roberto GirelliH-Index: 18
view all 11 authors...
Background and aims Radiofrequency ablation (RFA) is a well-recognized local ablative technique applied in the treatment of different solid tumors. Intraoperative RFA has been used for non-metastatic unresectable pancreatic ductal adenocarcinoma (PDAC), showing increased overall survival in retrospective studies. A novel RFA probe has recently been developed, allowing RFA under endoscopic ultrasound (EUS) guidance. Aim of the present study was to assess the feasibility and safety of EUS-guided R...
42 CitationsSource
#1Jun-Ho Choi (DU: Dankook University)H-Index: 18
#2Dong-Wan Seo (UOU: University of Ulsan)H-Index: 40
Last. Myung-Hwan Kim (UOU: University of Ulsan)H-Index: 89
view all 7 authors...
Background Radiofrequency ablation (RFA) has been increasingly employed in experimental and clinical settings for the management of pancreatic lesions. This study aimed to assess the safety and efficacy of endoscopic ultrasound (EUS)-guided RFA for benign solid pancreatic tumors. Methods In a single-center, prospective study, 10 patients with benign solid pancreatic tumors underwent EUS-RFA. After the RFA electrode had been inserted into the pancreatic mass, the radiofrequency generator was acti...
38 CitationsSource
BACKGROUND AND AIMS: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for the treatment of pancreatic neoplasm. We evaluated the feasibility, safety, and technical success of pancreatic EUS-RFA performed in a single center. METHODS: 9 consecutive patients (8 with pancreatic adenocarcinoma and 1 with renal cancer metastasis) were referred for EUS-RFA between November 2016 and July 2017. EUS-RFA was performed using 18-gauge internally cooled electrode with a ...
38 CitationsSource
#1Tom Malikowski (Mayo Clinic)H-Index: 1
#2Ferga C. Gleeson (Mayo Clinic)H-Index: 28
Last. Michael J. Levy (Mayo Clinic)H-Index: 107
view all 13 authors...
4 CitationsSource
Cited By5
#1Isabella FrigerioH-Index: 17
#2Salvatore PaiellaH-Index: 23
Last. G. FiorentiniH-Index: 14
view all 22 authors...
Abstract null null Background null Local ablation of pancreatic cancer has been suggested as an option to manage locally advanced pancreatic cancer (LAPC) although no robust evidence has been published to date to support its application. The aim of this study is to compare overall survival (OS) and progression-free survival (PFS) in patients receiving both radiofrequency ablation (RFA) and conventional chemoradiotherapy (CHRT) with patients receiving CHRT only. null null null Methods null This i...
#1Christoph F Dietrich (John Radcliffe Hospital)
#2Barbara Braden (John Radcliffe Hospital)H-Index: 43
Last. Christian JenssenH-Index: 18
view all 3 authors...
PURPOSE OF REVIEW To update on recent advances in interventional endoscopic ultrasound (INVEUS) techniques. RECENT FINDINGS The introduction of linear echoendoscopes with larger instrument channels and the combined development of new tools and devices have enabled various new applications of minimally invasive endoscopic ultrasound (EUS)-guided transluminal interventions of the pancreas, biliary system and peri-gastrointestinal structures. In this review, EUS-guided interventions are discussed a...
Prognosis of unresectable pancreatic cancer is poor with the rate of surviving more than 5 years is less than 10% despite multi-modalities treatment. The American Society of Clinical Oncology suggested that all patients with metastatic pancreatic cancer should be offered information about clinical trials. Endoscopic ultrasound guided radio frequency ablation has been recently used in patients with advanced stage pancreatic cancer in a few studies. This article has reviewed information from publi...
#1Michael MakarH-Index: 3
#2Eric Zhao (RU: Rutgers University)H-Index: 4
Last. Amy TybergH-Index: 21
view all 3 authors...
Pancreaticobiliary malignancies arise from different areas within the pancreas and biliary tree. Endoscopic ultrasound (EUS) is a well-recognized diagnostic and therapeutic modality in the treatment of pancreaticobiliary diseases, and more specifically, pancreaticobiliary malignancies. Traditionally used for diagnostic purposes, EUS plays a critical role in tissue sampling and cancer staging. The emergence of the new field of interventional EUS has allowed EUS to also play a critical role in the...
1 CitationsSource